20.500.12556/DiRROS-15225 Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77years (range, 48–91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47–69), whereas it was 68% (95% CI, 50–82) in treatment-naïve and 50% (95% CI, 35–65) in pretreated patients. The median progression-free survival was 9.5months (95% CI, 4.7–14.3), whereas it was 10.6months (95% CI, 5.5–15.7) in first-line and 9.1months (95% CI, 3.1–15.1) in pretreated patients. After a median follow-up of 11.0months, the median overall survival was 18.2 months (95% CI, 13.2–23.1). In patients with measurable brain metastases (n=11), the intracranial ORR was 46% (95% CI, 17–77). Capmatinib showed a manageable safety profile. Grade⩾3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting. non-small cell lung carcinoma -- drug therapy -- genetics molecular targeted therapy real-world data capmatinib targeted therapy nedrobnocelični karcinom pljuč -- terapija z zdravili -- genetika molekularna tarčna terapija podatki iz resničnega življenja capmatinib tarčna terapija true false true Sage Publications Angleški jezik Ni določen © The Author(s), 2022 Neznano 2022-06-24 12:43:52 2022-06-24 12:43:54 2022-08-21 03:36:09 0000-00-00 00:00:00 2022 0 Velika Britanija 0 Nasl. z nasl. zaslona; Soavtorici iz Slovenije: Katja Mohorčič, Tanja Čufer; Opis vira z dne 20. 6. 2022; str. 1-22 Vol. 14 Jan./Dec. 2022 0000-00-00 PostprintKoncna VTisku NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 1758-8359 10.1177/17588359221103206 112187139 RAZ_Illini_Oliver_i2022.pdf RAZ_Illini_Oliver_i2022.pdf 1 7467E1DD43C59C8F03153BE0B26C2277 b3353ec2d75af4d37471bb9230e77f357f738ff5aaf4af5503bb8d40eb4becfb f1f75133-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=19971 RAZ_Illini_Oliver_i2022.pdf RAZ_Illini_Oliver_i2022.pdf 1 FBEF8A29938691C1E058C466F41E46F7 5952b29e576b7b711682ff6113b79bce68b503293d97f4f395449cac1a9076c3 f1e43757-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=19970 https://journals.sagepub.com/doi/pdf/10.1177/17588359221103206 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=19965 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0